Stockreport

Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) [Yahoo! Finance]

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF important new therapeutic option from second line for patients with follicular lymphoma (FL) in Europe In Western countries, relapsed or refractory FL affects 2-4 out [Read more]